Effects of the nitric oxide synthase inhibitor L-NAME on recognition and spatial memory deficits produced by different NMDA receptor antagonists in the rat

Neuropsychopharmacology

Volumn 35, Issue 12, 2010, Pages 2357-2366

  Boultadakis, Antonios ^a   Pitsikas, Nikolaos ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

ketamine; L NAME; MK 801; rat; recognition memory; spatial memory

Indexed keywords

DIZOCILPINE; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RECOGNITION; REFERENCE MEMORY; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; DIZOCILPINE MALEATE; DRUG INTERACTIONS; KETAMINE; MALE; MAZE LEARNING; MEMORY DISORDERS; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECOGNITION (PSYCHOLOGY);

EID: 77957988948     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.109     Document Type: Article

References (57)

1. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA et al (1993). Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50: 169-177. (Pubitemid 23077471)
2. Archer SL, Hampi V (1992). NG-mono-methyl-L-arginine causes nitric oxide synthesis in isolated arterial rings: trouble in paradise. Biochem Biophysic Res Commun 188: 590-596.
3. Bartolini L, Casamenti F, Pepeu G (1996). Aniracetam restores object recognition impaired by age, scopolamine and nucleus basalis lesions. Pharmacol Biochem Behav 53: 277-283.
4. Bernstein HG, Bogerts B, Keilhoff G (2005). The many faces of nitric oxide in schizophrenia. A review. Schizophr Res 78: 69-86.
5. Boultadakis A, Georgiadou G, Pitsikas N (2010). Effects of the nitric oxide synthase inhibitor L-NAME on different memory components as assessed in the object recognition task in the rat. Behav Brain Res 207: 208-214.
6. Cavoy A, Delacour J (1993). Spatial but not object recognition is impaired by aging in rats. Physiol Behav 53: 527-530.
7. Contestabile A, Monti B, Contestabile A, Ciani E (2003). Brain nitric oxide and its dual effect in neuroprotection/neurodegen-eration: understanding molecular mechanisms to devise drug approaches. Curr Med Chem 10: 1241-1253.
8. Costa E, Davis JM, Dong E, Grayson DR, Guidotti A, Tremolizzo L et al (2004). A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit Rev Neurobiol 16: 1-23.
9. Clinton SM, Haroutunian V, Davis KL, Meader-Woodraff JH (2003). Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160: 1100-1109.
10. Das I, Ramchand CN, Gliddon A, Hirsch SR (1998). Nitric oxide, free radicals and polyamines may have a role in membrane pathology of schizophrenia. Neuropsychobiology 37: 65-67. (Pubitemid 28143016)
11. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH (1991). Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 88: 6368-6371.
12. Day MD (1979). Autonomic Pharmacology. Experimental and Clinical Aspects. Churchill Livingston: New York.
13. De Lima MNM, Laranja DC, Bromberg E, Roesler R, Schroeder N (2005). Pre-or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav Brain Res 156: 139-143.
14. Ennaceur A (2010). One-trial object recognition in rats and mice: methodological and theoretical issues. Behav Brain Res print copy in press (originally published online 6 Jan 2010, at www.sciencedirect/bbr.2009.12.036).
15. Fejgin K, Palsson E, Wass C, Svensson L, Klamer D (2008). Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine. Neuropsy-chopharmacology 33: 1874-1883.
16. Freedman R (2003). Schizophrenia. N Engl J Med 349: 1738-1749.
17. Gage FH, Dunnett SB, Bjorklund A (1984). Spatial learning and motor deficits in aged rats. Neurobiol Aging 5: 43-48.
18. Garthwaite J (1991). Glutamate nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14: 60-67.
19. Geyer MA, Markou A (1994). Animal models of psychiatric disorders. In: Bloom FE, DL Kupfer (eds). Psychopharmacology, The Fourth Generation of Progress. Raven Press: New York, pp 787-798.
20. Haley JE, Wilcox GL, Chapman PF (1992). The role of nitric oxide in hippocampal long-term potentiation. Neuron 8: 211-216.
21. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004). Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors and dopamine release. Neuropsychopharma-cology 29: 1259-1269.
22. Jarrard L, Okaichi H, Steward O, Goldschmidt R (1984). On the role of the hippocampal connections in the performance of place and cue tasks: comparisons with damage to hippocampus. Behav Neurosci 98: 946-954.
23. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
24. Johansson C, Jackson DM, Svensson L (1997). Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology 131: 167-173.
25. Kirk RE (1968). Experimental Design: Procedures for the Behavioral Science. Brooks/Cole: Belmont, CA.
26. Klamer D, Engel JA, Svensson L (2001). The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology 156: 182-186.
27. Klamer D, Engel JA, Svensson L (2004). The neuronal selective nitric oxide synthase inhibitor, Nomega-propyl-L-arginine, blocks the effects of phencyclidine on prepulse inhibition and locomotor activity in mice. Eur J Pharmacol 503: 103-107.
28. Klamer D, Palsson E, Wass C, Archer T, Engel JA, Svensson L (2005a). Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat. Behav Brain Res 159: 95-103.
29. Klamer D, Palsson E, Wass C, Archer T, Engel JA, Svensson L (2005b). Antagonism of the nitric oxide synthase inhibitor L-NAME, of the effects of phencyclidine on latent inhibition in taste aversion conditioning. Behav Brain Res 161: 60-68. (Pubitemid 40719770)
30. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremmer JD et al (1994). Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
31. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
32. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
33. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
34. Martinez JL (1986). Memory: drugs and hormones. In: Martinez JL, Kessner RP (eds). Learning and Memory. A Biological View. Academic Press: San Diego, pp 127-163.
35. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
36. O'Dell TJ, Hawkins RD, Kandel ER, Arancio O (1991). Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci USA 88: 11285-11289.
37. Okaichi H, Oshima Y, Jarrard LE (1989). Scopolamine impairs both working and reference memory in rats: a replication and extinction. Pharmacol Biochem Behav 34: 599-602.
38. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991). NMDA antagonist neurotoxicity: mechanism and prevention. Science 254: 1515-1518.
39. Olton DS (1983). Memory functions and hippocampus. In: Seifert W (ed). Neurobiology of Hippocampus. Academic Press: New York, pp 335-369.
40. Palsson E, Finnerty N, Klamer D, Wass C, Svensson L, Lowry J (2009). Increased cortical nitric oxide release after phencyclidine administration. Synapse 63: 1083-1088.
41. Pitsikas N, Algeri S (1992). Deterioration of spatial and nonspatial reference and working memory in aged rats: protective effect of life-long calorie restriction. Neurobiol Aging 13: 369-373.
42. Pitsikas N, Boultadakis A, Sakellaridis N (2008). Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory. Neuroscience 154: 454-460.
43. Pitsikas N, Zisopoulou S, Sakellaridis N (2006). Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. J Neurosci Res 84: 299-305.
44. Pitsikas N, Zisopulou S, Tarantilis PA, Kanakis CD, Polissiou MG, Sakellaridis N (2007). Effects of the active constituents of Crocus sativus L., crocins, on recognition and spatial rats' memory. Behav Brain Res 183: 141-146. (Pubitemid 47348125)
45. Prast H, Philippu A (2001). Nitric oxide as modulator of neuronal function. Progr Neurobiol 64: 51-68.
46. Ramirez J, Garnica R, Boll MC, Montes S, Rios C (2004). Low concentrations of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients. Schizophr Res 68: 357-361.
47. Razoux F, Garcia R, Lena I (2007). Ketamine at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accum-bens. Neuropsychopharmacology 32: 719-727.
48. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and vivo. Br J Pharmacol 101: 746-752. (Pubitemid 20357206)
49. Reif A, Herterich S, Strobel A, Ehlis AC, Saur D, Jacop CP et al (2006). A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 11: 286-300.
50. Roberts RC, Roche JK, Conley RR (2005). Synaptic differences in the post-mortem striatum of subjects with schizophrenia: a stereological and utrastructural analysis. Synapse 56: 185-197.
51. Taneli F, Piridar S, Akdeniz F, Uyanik BS, Ari Z (2004). Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 35: 401-405.
52. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989). The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167: 127-135.
53. Verma A, Moghaddam B (1996). NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373-379.
54. Wass C, Archer T, Palsson E, Fejgin K, Alexandersson A, Klamer D et al (2006a). Phencyclidine affects memory in a nitric oxide-dependent manner. Working and reference memory. Behav Brain Res 174: 49-55.
55. Wass C, Archer T, Palsson E, Fejgin K, Klamer D, Engel JA et al (2006b). Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. Behav Brain Res 171: 147-153. (Pubitemid 43728400)
56. Wesierska M, Macias-Gonzales R, Bures J (1990). Differential effects of ketamine on the reference and working memory versions of the Morris water maze task. Behav Neurosci 104: 74-83.
57. Yilmaz N, Herken H, Cicek HK, Celik A, Yurekli M, Akyol O (2007). Increased levels of nitric oxide, cortisol and adrenome-dullin in patients with chronic schizophrenia. Med Princ Pract 16: 137-141.